Accessibility Menu
Atrium Therapeutics logo

Atrium Therapeutics(NASDAQ) RNA

Market Cap$234.52MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2026)-7%
5 YearN/A
1 YearN/A
1 Month+17%
$13.46
-1.82%
-0.25Today
After hours$13.46+$0.00 (+0.03%)
Atrium Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 13.712026-08-19
Atrium Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+12.65%USD 12.172026-08-12
1 month+16.58%USD 11.762026-07-20
3 month+5.14%USD 13.042026-05-21
Since inception-7.05%USD 14.752026-02-27

Atrium Therapeutics Financials at a Glance

Market Cap

$234.52MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$27.35

Net Income (TTM)

-$78.83

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

0.37 (Low)

Price

$13.46

Volume

218,805

Open

$13.75

Previous Close

$13.48

Daily Range

$13.20 - $13.88

52-Week Range

$11.13 - $16.77

Estimated Earnings Date

Nov 12, 2026

RNA News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Atrium Therapeutics

Atrium Therapeutics, Inc. makes medicine for people with heart disease. The company uses genetic tools to treat serious heart problems. These treatments help patients with rare and inherited conditions.

Fixing Hearts With Genetic Tools

  • ATR 1072: Investigational therapy targeting the PRKAG2 gene for patients with rare heart rhythm disorders.
  • ATR 1086: Treatment using gene-silencing technology to address a specific type of heart muscle disease by targeting the PLN gene.
  • Research Programs: Pipeline initiatives focused on developing new therapies for undisclosed rare genetic cardiology targets.

The Path to Independence

  • Completed the separation from Avidity Biosciences on Feb. 26, 2026.
  • Earned a $15 million milestone payment from a collaboration with Bristol Myers Squibb during the first half of 2026.
  • Received FDA clearance to begin clinical trials for the ATR 1072 program.
  • Obtained regulatory approval from Health Canada to initiate study sites in Canada.

Reaching the Heart Directly

Atrium uses a delivery platform that combines monoclonal antibodies, which act as homing devices to find specific cells, with genetic material. This technology allows the company to deliver medicine directly to heart tissue to address the underlying genetic causes of disease.

Revenue and Cash Reserves

  • Collaboration revenue was $22.6 million for the six-month period ended June 30, 2026, up $17.2 million year over year.
  • Net loss was $36.8 million for the six-month period ended June 30, 2026, compared to $20.3 million year over year.
  • Cash, cash equivalents, and short-term investments totaled $263.9 million as of June 30, 2026.
  • Market capitalization was $210.9 million based on current data.
  • Full-time employee count reached 511 as of June 2026.

Bottom Line

Atrium has transitioned from a division of Avidity Biosciences to an independent biotechnology firm focused on precision cardiology. The company is advancing a pipeline of gene-based candidates to address high unmet needs in rare cardiac conditions.

AI Generated • Aug 14, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Kathleen Gallagher

Website

www.atriumtherapeutics.com

Headquarters

San Diego, CA 92121, US

RNA Financials

Key Financial Metrics (TTM)

Gross Margin

97.90%

Operating Margin

-374.21%

Net Income Margin

-361.26%

Return on Equity

-39.08%

Return on Capital

-36.41%

Return on Assets

-30.26%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$234.52MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

17.11M

Volume

218.81K

Avg. Volume

193.82K

Financials (TTM)

Gross Profit

$23.00M

Operating Income

-$87.93M

EBITDA

-$86.67M

Operating Cash Flow

-$54.32M

Capital Expenditure

-$3.01M

Free Cash Flow

-$57.33M

Cash & ST Invst.

$264.21M

Total Debt

$1.68M

Atrium Therapeutics Performance Analysis

Atrium Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-12-31USD 9,764,000N/A
20242024-12-31USD 10,897,00011.6%
20252025-12-31USD 18,618,00070.9%
Atrium Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-312185.8%
Q22026-06-30-84.7%
Atrium Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-12-31USD -0.37N/A
20242024-12-31USD -1.47293.4%
20252025-12-31USD -2.8997.0%
Atrium Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-3142.9%
Q22026-06-30-21.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$3.00M

N/A

Gross Profit

$2.66M

N/A

Gross Margin

88.58%

N/A

Market Cap

$234.52MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$458.94K

N/A

Employees

511

N/A

Net Income

-$20.19M

N/A

EBITDA

-$22.28M

N/A

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$264.21M

N/A

Total Debt

$1.68M

N/A

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$1.68M

N/A

Return on Assets

-30.26%

N/A

Return on Invested Capital

-35.31%

N/A

Free Cash Flow

-$3.96M

N/A

Operating Cash Flow

-$3.93M

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,651.63-0.01%
^DJIDJI
$52,821.81-0.01%
^IXICNASDAQ
$26,044.14-0.01%
BTCBitcoin
$72,669.00+0.06%

Trending Stocks

Symbol / CompanyPricePrice Chg
BITOProShares Trust - ProShares Bitcoin ETF
$9.81+0.06%
SPCXSpace Exploration Technologies
$134.00-0.04%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.88-0.03%
IBITiShares Bitcoin Trust
$41.20+0.06%

Questions About RNA

What is the current price of Atrium Therapeutics?

Atrium Therapeutics is trading at $13.48 per share.

What is the 52-week range for Atrium Therapeutics?

Over the past 52 weeks, Atrium Therapeutics has traded between $11.13 and $16.77.

How much debt does Atrium Therapeutics have?

As of the most recent reporting period, Atrium Therapeutics reported total debt of $1.68M.

How much cash does Atrium Therapeutics have on hand?

Atrium Therapeutics reported $72.65M in cash and cash equivalents in its most recent financial results.

What is Atrium Therapeutics’s dividend yield?

Atrium Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services